scholarly journals Manipulations and age-appropriateness of oral medications in pediatric oncology patients in Sweden: Need for personalized dosage forms

2022 ◽  
Vol 146 ◽  
pp. 112576
Author(s):  
Jenny Johannesson ◽  
Paula Hansson ◽  
Christel A.S. Bergström ◽  
Mattias Paulsson
Keyword(s):  
Pediatric Oncology ◽  
Dosage Forms ◽  
Oncology Patients ◽  
Oral Medications

Psychosocial Functioning of Fathers of Pediatric Oncology Patients

2006 ◽  
Author(s):  
Kristina K. Hardy ◽  
Melanie J. Bonner ◽  
Katherine C. Hutchinson ◽  
Victoria W. Willard
Keyword(s):  
Pediatric Oncology ◽  
Psychosocial Functioning ◽  
Oncology Patients

Perceived Impact of Illness During Treatment in Pediatric Oncology Patients

2007 ◽  
Author(s):  
Stephen R. Lassen ◽  
Brent Collett ◽  
Stan Whitsett ◽  
Debra Friedman
Keyword(s):  
Pediatric Oncology ◽  
Oncology Patients ◽  
Perceived Impact

New guidelines for the clinical management of febrile neutropenia and sepsis in pediatric oncology patients

2007 ◽  
Vol 83 (7) ◽  
pp. 54-63 ◽  
Author(s):  
Ana Verena Almeida Mendes ◽  
Roberto Sapolnik ◽  
Núbia Mendonça
Keyword(s):  
Febrile Neutropenia ◽  
Pediatric Oncology ◽  
Clinical Management ◽  
Oncology Patients ◽  
New Guidelines

Risk factors associated with the development of oral mucositis in pediatric oncology patients: Systematic review and meta‐analysis

Oral Diseases ◽  
2021 ◽  
Author(s):  
Amanda de Farias Gabriel ◽  
Felipe Martins Silveira ◽  
Marina Curra ◽  
Lauren Frenzel Schuch ◽  
Vivian Petersen Wagner ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Oral Mucositis ◽  
Pediatric Oncology ◽  
Meta Analysis ◽  
Oncology Patients ◽  
Factors Associated

Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for Pneumocystis jirovecii pneumonia in pediatric oncology patients

2020 ◽  
pp. 107815522097904
Author(s):  
Monica Awad ◽  
Caroline M Sierra ◽  
Elhaam Mesghali ◽  
Khaled Bahjri
Keyword(s):  
Pediatric Oncology ◽  
Retrospective Cohort ◽  
Hematologic Malignancies ◽  
Primary Objective ◽  
Pneumocystis Jirovecii ◽  
Pneumocystis Jirovecii Pneumonia ◽  
Weekly Dose ◽  
Single Center ◽  
Oncology Patients ◽  
Prophylaxis Therapy

Current recommendations for prophylaxis of Pneumocystis jirovecii pneumonia in oncology patients include administration of trimethoprim/sulfamethoxazole (TMP/SMX) three times weekly or the same total weekly dose given daily. The primary objective of this study was to evaluate the efficacy of two consecutive days per week of TMP/SMX for prevention of Pneumocystis jirovecii pneumonia (PJP) in pediatric oncology patients. A retrospective cohort, single-center analysis was conducted in oncology patients 21 years and younger who received TMP/SMX for PJP prophylaxis between February 1, 2013 and July 31, 2017. Changes to the prophylaxis regimen were documented and analyzed. A total of 322 patients received TMP/SMX on two consecutive days per week for PJP prevention, of whom four had confirmed PJP (1.3%). Neutropenia was the most common reason for switching to alternative prophylaxis therapy (11.5%). Two consecutive prophylaxis days with TMP/SMX may be insufficient to prevent PJP in children with hematologic malignancies. Neutropenia remains a barrier for TMP/SMX use for PJP prophylaxis. Further studies to compare PJP incidence in children receiving alternative prophylaxis regimens should be considered.

Diagnosis of Invasive Fungal Infection Among Pediatric Oncology Patients

2019 ◽  
Vol 41 (8) ◽  
pp. 596-600 ◽  
Author(s):  
Erica I. Hodgman ◽  
Jeffrey Compton ◽  
Faisal G. Qureshi ◽  
Joseph T. Murphy
Keyword(s):  
Fungal Infection ◽  
Pediatric Oncology ◽  
Invasive Fungal Infection ◽  
Oncology Patients

scholarly journals Updated List of Light-Sensitive Oral Medications

2019 ◽  
Vol 55 (6) ◽  
pp. 349-365
Author(s):  
Scott Perkins ◽  
Adam Evans ◽  
Allison King
Keyword(s):  
Dosage Form ◽  
Drug Information ◽  
Dosage Forms ◽  
Drug Products ◽  
Solid Dosage ◽  
Oral Medications ◽  
Information Center ◽  
Oral Liquid ◽  
Liquid Products ◽  
Professional Resources

The Campbell University Drug Information Center supports health professionals by providing responses to drug-related inquiries. An inquiry was received by the Drug Information Center for a comprehensive list of oral solutions which should be protected from light. In investigating this request for information, a list of light-sensitive oral prescription drug products published in Hospital Pharmacy in 2009 was identified. This discovery highlighted the need for both an updated list and one which distinguished oral solid products and oral liquid products. The purpose of this project was to update the previously published list and to distinguish between oral solid and liquid dosage forms. The process of updating this list entailed several professional resources. A list of all oral products was obtained and then sorted to clearly identify which products were available in oral solid dosage form only, oral liquid dosage form only, and both dosage forms. Once delineated, the product labels for each medication were scoured for language indicating the product is light sensitive.

Sign in / Sign up

Export Citation Format

Share Document